Dual Roles of METCAM in the Progression of Different Cancers by Wu, Guang-Jer
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 853797, 13 pages
doi:10.1155/2012/853797
Review Article
DualRolesofMETCAM in the Progression of DifferentCancers
Guang-Jer Wu1,2
1Department of Microbiology and Immunology, Emory University, School of Medicine, Atlanta, GA 30322, USA
2Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 32023, Taiwan
Correspondence should be addressed to Guang-Jer Wu, gwu@emory.edu
Received 16 October 2011; Revised 31 December 2011; Accepted 12 January 2012
Academic Editor: Omer Faruk Hatipoglu
Copyright © 2012 Guang-Jer Wu. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
METCAM, an integral membrane cell adhesion molecule (CAM)i nt h eIg-like gene superfamily, is capable of performing typical
functions of CAMs, such as mediating cell-cell and cell-extracellular interactions, crosstalk with intracellular signaling pathways,
and modulating social behaviors of cells. METCAM is expressed in about nine normal cells/tissues. Aberrant expression of
METCAM has been associated with the progression of several epithelial tumors. Further in vitro and in vivo studies show that
METCAM plays a dual role in the progression of diﬀerent tumors. It can promote the malignant progression of several tumors.
On the other hand, it can suppress the malignant progression of other tumors. We suggest that the role of METCAM in the
progression of diﬀerent cancer types may be modulated by diﬀerent intrinsic factors present in diﬀerent cancer cells and also in
diﬀerent stromal microenvironment. Many possible mechanisms mediated by this CAM during early tumor development and
metastasis are suggested.
1.Introduction
Human METCAM (huMETCAM), a CAM in the immu-
noglobulin-like gene superfamily, is an integral membrane
glycoprotein. Alternative names for METCAM are MUC18
[1], CD146 [2], MCAM [3], MelCAM [4], A32 [5], and S-
endo 1 [6]. To avoid confusion with mucins and to reﬂect its
biological functions, we have renamed MUC18 as METCAM
(metastasis CAM), which means an immunoglobulin-like
CAM that aﬀects or regulates metastasis, [7]. The huMET-
CAM has 646 aminoacids that include a N-terminal extra-
cellular domain of 558 aminoacids, which has 28 aminoacids
characteristics of a signal peptide sequence at its N-termi-
nus, a transmembrane domain of 24 aminoacids (amino
acid number 559–583), and a cytoplasmic domain of 64
aminoacids at the C-terminus. HuMETCAM has eight
putative N-glycosylation sites (Asn-X-Ser/Thr), of which six
are conserved, and are heavily glycosylated and sialylated
resulting in an apparent molecular weight of 113,000–
150,000. The extracellular domain of the protein comprises
ﬁve immunoglobulin-like domains (V-V-C2-C2-C2) [1, 7]
and an X domain [7]. The cytoplasmic tail contains peptide
sequences that will potentially be phosphorylated by protein
kinase A (PKA), protein kinase C (PKC), and casein kinase 2
(CK 2)[ 1, 7, 8]. My lab has also cloned and sequenced
the mouse METCAM (moMETCAM) cDNA, which contains
648 aminoacids with a 76.2% identity with huMETCAM,
suggesting that moMETCAM is likely to have biochemical
properties and biological functions similar to the human
counterpart [9]. The structure of the huMETCAM protein
is depicted in Figure 1, suggesting that METCAM, similar
to most CAMs, plays an active role in mediating cell-
cell and cell-extracellular interactions, crosstalk with many
intracellular signaling pathways, and modulating the social
behaviors of cells [7].
HuMETCAM is expressed in a limited number of normal
tissues, such as hair follicular cells, smooth muscle cells,
endothelial cells, cerebellum, normal mammary epithelial
cells, basal cells of the lung, activated T cells, intermediate
trophoblast [10], and normal nasopharyngeal epithelial cells
[11]. The protein is overly expressed in most (67%) ma-
lignant melanoma cells [1], and in most (more than 80%)
premalignant prostate epithelial cells (PIN), high-grade
prostatic carcinoma cells, and metastatic lesions [12, 13].
HuMETCAM is also expressed in other cancers, such as
gestational trophoblastic tumors, leiomyosarcoma, angiosar-
coma, haemangioma, Kaposi’s sarcoma, schwannoma, some
lung squamous and small cell carcinomas, some breast2 Journal of Oncology
cancer, some neuroblastoma [10], and also nasopharyngeal
carcinoma [11] and ovarian cancer [14].
It is now well documented that in addition to tissue-
speciﬁc signatures in diﬀerent cancer types, cancers from
diﬀerent tissues also express some common genes [15–17].
O n eg r o u po ft h e mi sc e l la d h e s i o nm o l e c u l e s( CAMs).
CAMs do not merely act as a molecular glue to hold
together homotypic cells in a speciﬁc tissue or to facilitate
interactions of heterotypic cells; CAMs also actively govern
the social behaviors of cells by aﬀecting the adhesion status
of cells and modulating cell signaling [18]. They control
cell motility and invasiveness by mediating the remodeling
of cytoskeleton [18]. They also actively mediate the cell-
to-cell and cell-to-extracellular matrix interactions to allow
cells to constantly respond to physiological ﬂuctuations
and to alter/remodel the surrounding microenvironment for
survival [19]. They do so by crosstalk with cellular surface
growth factor receptors, which interact with growth factors
that may be secreted from stromal cells or released from
circulation and embedded in the extracellular matrix [18,
19]. Thus, an altered expression of CAMs aﬀects the motility
and invasiveness of many tumor cells in vitro and metastasis
in vivo [18, 19]. CAMs also play an important role in the
favorable soil that provides a proper microenvironment at
a suitable period to awaken the dormant metastatic tumor
cells to enter into an aggressive growth phase. Actually, the
metastatic potential of a tumor cell, as documented in many
carcinomas, is the consequence of a complex participation of
many over- and under-expressed CAMs [18, 19]. Based on
the above information, aberrant expression of huMETCAM
may also aﬀect the motility and invasiveness of many tumor
cells invitroandmetastasisinvivo. Itislogicaltohypothesize
that HuMETCAM/MUC18 should play an important role
in promoting the malignant progression of many cancer
types [7, 18]. However, recently we observed an unexpected
opposite function of METCAM/MUC18 in the malignant
progression of a mouse melanoma subline and ovarian
cancer cells, in which it functioned as a tumor and metastasis
suppressor (Wu, unpublished results). In this paper, we will
review its dual roles in the tumorigenesis and metastasis in
diﬀerent cancer types.
2.METCAM and Tumorigenesis
METCAM-induced tumorigenesis has been studied in mel-
anoma, prostate cancer, breast cancer, and ovarian cancer.
Overexpression of METCAM may have no eﬀect, a negative
eﬀect, or a positive eﬀect on tumorigenesis, dependent upon
the cell lines used, as shown in the following.
2.1. METCAM and Melanoma Tumorigenesis. Overexpres-
sion of METCAM had a slight tumor suppression eﬀect
on tumorigenesis of human melanoma cells in xenograft
mice [20], as shown in Figure 2,b u ti th a dn oe ﬀect on
tumorigenesis of two sublines, number 3 and number 10,
of the mouse melanoma cell line K1735 in syngeneic mice
[21]. Figure 3 shows only the eﬀect of moMETCAM on the
tumorigenesis of K1735-3.
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Figure 1: HuMETCAM protein structure. SP stands for signal pep-
tide sequence: V1, V2, C2, C2 ,a n dC 2    for ﬁve Ig-like domains
(each held by a disulﬁde bond) and X for one domain (without any
disulﬁde bond) in the extracellular region, and TM for transmem-
branedomain.Pstandsforﬁvepotentialphosphorylationsites(one
for PKA, three for PKC, and one for CK2) in the cytoplasmic tail.
The six conserved N-glycosylation sites are shown as wiggled lines
intheextracellulardomainsofV1,theregionbetweenC2  andC2  ,
C2  ,a n dX .
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Figure 2: Eﬀect of overexpression of huMETCAM on tumor for-
mation of two human melanoma cell lines, SK and XP-44 [20].
MELCAM-SK and MELCAM-XP-44 were two clones of human
melanoma cell lines, SK and XP-44, respectively, which were trans-
fectedwithhuMETCAM ande xpr essedahighlev elofhuMETCAM.
Statistical analysis was not possible because detailed data was not
provided.
Only one group showed that overexpression of METCAM
increased tumorigenesis of a human melanoma cell line in
xenograft mice [3]; however, the results were questionable
because only the tumorigenicity of one mouse injected with
METCAM-expressing clone and one mouse with control
cells was determined, and thus no standard deviations were
indicated and no statistical analysis was done, as shown in
Figure 4.
The most compelling evidence for its tumor suppressor
eﬀect is in the subline number 9 of the mouse melanoma
cell line K1735 (K9) in syngeneic C3H mice. Overexpression
of moMETCAM in the K9 cells decreased subcutaneous
tumorigenesis in immunocompetent syngeneic C3H mice
[22, 23, and unpublished results], as shown in Figure 5.Journal of Oncology 3
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Figure 3: Eﬀect of overexpression of moMETCAM on tumor for-
mation of a mouse melanoma cell line K1735 subline number 3
[21]. METCAM-K3H and METCAM-K3L were two K3 clones
transfected with moMETCAM cDNA; expressed a high and a low
level of moMETCAM, respectively. Vector-K3, as a negative control,
was one clone transfected with an empty vector and did not
express any moMETCAM. Asterisk was the reference for the P value
calculation. The P values should be compared with the reference
(asterisk) on the same row.
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Figure 4: Eﬀe c to fo v e r e x p r e s s i o no fhuMETCAM on tumor
formationofahumanmelanomacelllineSB-2[3].SB-2isahuman
melanoma cell line, which did not express any huMETCAM.S B - 2 -
neo is the SB-2 cells transected with the empty vector, as a negative
control.MELCAM isacloneoftheSB-2cellswhichweretransfected
withhuMETCAM cDN AandexpressedahighlevelofhuMETCAM.
Since tumor formation was only shown in one nude mouse for each
clone, statistical analysis was not possible.
2.2. METCAM and Breast Cancer Tumorigenesis. Shih et al.
showed that METCAM was not expressed in MCF-7 cell line
[24], and they showed that the overexpression of huMET-
CAM inMCF-7 cellssuppressedtumorformationofthecells
in SCID mice, as shown in Figure 6, suggesting that MET-
CAM is a possible tumor suppressor in breast cancer [24].
We have conﬁrmed from their Western blot and immun-
ohistochemistry results that METCAM is not expressed in
MCF-7 cells (0%), very weakly expressed in SK-BR-3 cells
(5%), and weakly expressed, though slightly higher levels
than the above two cells lines, in the human mammary
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Figure 5: Eﬀect of overexpression of moMETCAM on tumor
formation of a mouse melanoma K1735 subline number 9 (K9)
in immune competent syngeneic C3H mice. METCAM-K9H and
METCAM-K9L were two transfected clones, which expressed a
high and a low level of moMETCAM, respectively. Vector-K9 was
one clone transfected with the empty vector, as a negative control.
K9 was parental K1735 subline number 9 cells, also as a negative
control.Rev-K9,inwhichthemoMETCAM cDNAwasinsertedinto
the expression vector in antisense orientation, is also as a control
clone.Vector-K9,K9,andRev-K9didnotexpressanymoMETCAM.
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Figure 6: Eﬀect of overexpression of huMETCAM on tumor for-
mation of a human breast cancer cell line MCF-7 [24]. METCAM-
MCF-7 was a clone, which expressed a high level of huMET-
CAM/MUC18 after transfection with the cDNA. Vector MCF-7 was
a clone, which did not express any huMETCAM after transfection
with an empty vector. Cells were injected subcutaneously into
female SCID mice [24].
cancer cell lines, MDA-MB-231 (a low metastatic cell line)
(16%), and MDA-MB-468 (a high metastatic cell line)
(22%), as shown in Figure 7.
Recently gene expression proﬁles of breast cancer cell
lineshaveindicatedthatthegeneexpressionproﬁlesofMCF-
7 andSK-BR3aremorecloselyrelatedtotheluminalsubtype
of the breast cancers, whereas those of MDA-MB-231 and
MDA-MB-468 are more closely related to the basal-like
subtype [25, 26]. It appeared that METCAM is not or weakly
expressed in cell lines established from luminal subtypes,
but it is moderately expressed in cell lines established from4 Journal of Oncology
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Figure 7: Expression of huMETCAM in four human breast cancer
cell lines, MCF-7, SK-BR-3, MDA-MB-231,a n dMDA-MB-468.
SK-Mel-28, a human melanoma cell line, which expressed a very
high level of huMETCAM, was used as a positive control (100%).
Two human prostate cancer cell lines, DU145 and LNCaP, which
expressed diﬀerent levels of huMETCAM (60% and 0%, resp.) were
used as positive and negative controls.
basal-like subtypes, MDA-MB-231 and MDA-MB-468.R e -
cently Ouhtit et al. [27] found that overexpression of
METCAM inhibited the in vitro invasiveness of MDA-
MB-231 cells, supporting the notion of Shih et al. On the
contrary, Garcia et al. [28]a n dZ a b o u oe ta l .[ 29]s u p p o r t e d
the opposite role of METCAM in the progression of human
breast cancer cells in that it plays a role of tumor promoter.
However, all three groups did not substantiate their claim
with studies in animal models. To resolve this controversy,
we recently reinvestigated the role of METCAM in the
tumorigenesis of human breast cancer cells in animal models
and found that overexpression of METCAM promoted
the tumorigenesis of four human breast cancer cell lines,
MCF7, SK-BR-3, MDA-MB-231,a n dMDA-MB-468 [30, 31].
Tumorigenesis of MCF-7 in female SCID mice [30] is shown
in Figure 8, and that of SK-BR-3 in female nude mice [31]i n
Figure 9.
Thus, the tumor suppression role of METCAM in
tumorigenesis of human breast cancer cells is not supported
by the above evidence. On the contrary, it suggests the
alternative notion that METCAM increased tumorigenesis
and perhaps also the metastasis of human breast cancer cells.
2.3. METCAM and Ovarian Cancer Tumorigenesis. Recently,
bothourgroupandanothergroupfoundthatMETCAM was
upregulated in human ovarian cancer specimens, suggesting
that METCAM may be a marker for the poor prognosis of
ovarian cancer patients [14, 32], and that METCAM may
play a positive role in the development of ovarian cancer
[14, 32]. However, preliminary animal tests (injection of BG-
1 cells in nonorthotopic, subcutaneous sites of female nude
mice) show that overexpression of METCAM did not have
any signiﬁcant eﬀect on the tumor formation of a human
ovarian cancer cell line, BG-1 (data not shown). To rule out
the possibility that this eﬀectmight be an artifactbecausethe
tests were carried out in the nonorthotopic, subcutaneous
sites, which did not provide a proper microenvironment
for tumorigenesis, we carried out further tests of the eﬀect
of overexpression of METCAM on tumorigenesis of BG-
1 cells by injecting the clones in an orthotopic site, the
intraperitoneal cavity of female SCID mice. We found that
tumorigenesis of BG-1 clones was also very poor, suggesting
thatestrogensupplementbysubcutaneousimplantationmay
enhance the tumorigenesis of BG-1 cells in both immun-
odeﬁcient mice. Nevertheless, the test of the eﬀect of over-
expression of METCAM on tumorigenesis of BG-1 cells in
orthotopic sites had a somewhat suppressive eﬀect, as shown
in Figure 10 [33].
We also carried out animal studies by using another
human ovarian cancer cell line, SK-OV-3 and found that
overexpression of METCAM suppressed tumorigenesis of
SK-OV-3 cells at both nonorthotopic, subcutaneous sites, as
well as an orthotopic site (the intraperitoneal cavity) [34], as
shown in Figure 11.
2.4. METCAM and Prostate Cancer Tumorigenesis. Overex-
pression of METCAM signiﬁcantly increases the tumor-take
and promote tumorigenicity and tumorigenesis of a human
prostate cancer cell line, LNCaP, as shown in Figure 12 [35,
36].
2.5. METCAM Tumorigenesis of Other Cancer Cell Lines. We
found that moMETCAM was expressed at a higher level in
a mouse angiosarcoma clone, SVR,w h i c hw a st r a n s f e c t e d
with H-Ras, than in the immortalized normal endothelial
cell line control, MS-1 (Figure 13). The higher level of
moMETCAM expression appeared to correlate with the
higher tumorigenicity of the SVR cell line [7, 37], suggesting
apositiveroleforMETCAM inpromotingangiosarcoma[7].
There is a negative correlation of METCAM expression
with the human nasopharyngeal carcinoma specimens, sug-
gestingthatMETCAM mayalsoplayatumorsuppressorrole
in the tumorigenesis of nasopharyngeal carcinoma [11]. A
t u m o rs u p p r e s s o rr o l eo fMETCAM may also be implicated
in haemangiomas, since METCAM expression was decreased
during the progression of haemangiomas [38].
3.METCAM andMetastasis
METCAM-induced metastasis has been studied in melano-
ma, prostate cancer, osteosarcoma, and ovarian cancer lines.
Overexpression of METCAM in melanoma cells mostly have
ap o s i t i v ee ﬀect on the metastasis of human melanoma cell
linesinimmunodeﬁcientmice(bothathymicnudeandSCID
mice) [3, 20], mouse melanoma cell lines in syngeneic mice
[7, 21], and a human prostate cancer cell line, LNCaP,i n
nude mice [7, 13, 36]. Overexpression of METCAM also
has a positive eﬀect on the metastasis of osteosarcoma cell
lines [39]. Surprisingly, we have recently found that over-
expression of METCAM has a negative eﬀect on the metasta-
sis of one subline, number 9, of mouse melanoma cell K1735
[22, 23, and our unpublished results] and ovarian cancer cell
lines [30–32]. Details are described in the following.
3.1. METCAM and Melanoma Metastasis. HuMETCAM was
originally found to be abundantly expressed on the cellular
surface of most malignant human melanomas; since then,
it has been postulated to play a role in the progression ofJournal of Oncology 5
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human melanoma [1]. This notion is also supported by
the positive correlation of moMETCAM expression with
the metastatic ability of several mouse melanoma cells
lines [9]. Deﬁnitive proof comes from the results that the
stably ectopic expression of the huMETCAM cDNA gene
in three nonmetastatic human cutaneous melanoma cell
lines increases the metastatic abilities of these cell lines in
immune-deﬁcient mouse models [3, 20]. Furthermore, the
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genicity of a human ovarian cancer cell line BG-1 in an orthotopic
site (the intraperitoneal cavity) in female SCID mice. Clone 2-1
expressed 130% of METCAM. The vector control, pooled clone 3,
expressed 12% of METCAM.
stable, ectopic expression of moMETCAM cDNA in two
low-metastatic mouse melanoma cell lines increases the
metastatic abilities of these cell lines in immune-competent
syngeneic mice [21]. However, METCAM enables melanoma
cells to establish pulmonary metastasis only when the cells
are injected into the tail vein (experimental metastasis assay)
[3, 20, 21], thus bypassing the initial stages of metastasis. No
metastasiswasfoundwhenMETCAM-expressingmelanoma
cells were injected subcutaneously (spontaneous metastasis
assay) either in immune-deﬁcient mouse models [3, 20]o r
in immune-competent syngeneic mouse models [21]. Taken
together, METCAM deﬁnitely promotes the metastasis of
melanoma cells, but at later stages [7]; thus overexpression6 Journal of Oncology
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Figure 14: Enforced expression of moMETCAM suppressed lung
nodule formation of mouse melanoma K9 cells in syngeneic C3H
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of METCAM did not initiate the metastasis of melanoma
cells. This result is consistent with the recent observation
that ﬁbroblast growth factor 2, but neither huMETCAM
nor integrin actually initiates the malignant progression of
subcutaneous melanocyte into melanoma [40].
In contrast to these results, overexpression of moMET-
CAM in one mouse melanoma cell line K1735 subline
number 9 (K9) decreased pulmonary lung nodule forma-
tion when cells were injected into tail veins (experimental
metastasis test) [22, 23, and unpublished results], as shown
in Figure 14.
3.2. METCAM and Prostate Cancer Metastasis. Overexpres-
sion of METCAM is not limited to melanoma as previously
thought [7, 10]. Our group has pioneered the successful
determination of huMETCAM expression in prostate can-
cer cells and tissues using our chicken polyclonal anti-
huMETCAM and carried out extensive studies of huMET-
CAM-mediated prostate cancer metastasis [8]. We have used
molecular biological and immunological methods to study
the expression of huMETCAM in three established prostate
cancer cell lines and human prostate cancer tissues, and in
immunohistochemical studies of paraﬃn-embedded human
prostate cancer tissue sections [7, 8, 12, 13]. From the results,
wehavesuggestedthathuMETCAM maybeanewdiagnostic
marker for the metastatic potential of human prostate
cancer. This is further corroborated by results of a positive
correlation of moMETCAM expression with the progression
of mouse prostate adenocarcinoma in a transgenic mouse
model, TRAMP [41]. From these results, we have also
suggested that huMETCAM may be a key determinant in
promoting tumorigenesis and metastasis of human prostate
cancer cells [7]. To test this hypothesis, we determined the
eﬀect of ectopic expression of huMETCAM on the ability of
human prostate LNCaP cells to form tumor in the prostate
gland and to initiate metastasis in nude mice. We found
that overexpression of METCAM had a positive eﬀect on the
metastasis of the human prostate cancer cell, LNCaP, when
the cells were injected at the orthotopic site (the dorsolateral
lobes of the nude mice) [36]. The metastatic lesions were
found in multiple organs, such as seminal vesicles, ureter,
kidney, and periaortic lymph nodes [36]. Diﬀerent mice had
metastatic lesions in one or two organs, but all of them
had metastatic lesions in the lymph nodes. The parental
LNCaP c e l l s ,w h i c hd on o te x p r e s sa n yMETCAM, can form
tumors in the prostate, but these tumors did not manifest
any metastasis. The metastatic lesions in the bones were not
examined. But our recent preliminary results appear to show
that overexpression of METCAM may be able to enhance
establishmentofthegrowthofabone-homing C42Bclone of
LNCaP cells in nude mice. Further tests are in process [Wu et
al., unpublished results].
Takentogether,METCAM canactuallyinitiatethemetas-
tasisofLNCaPcells,thusaﬀectingtheprogressionofprostate
cancer cells at the early stage of metastasis [7, 36].
3.3. METCAM and Osteosarcoma Metastasis. Recently, one
group has shown that METCAM is overly expressed in two
of the six human osteosarcoma cell lines. Overexpression of
METCAM increased the spontaneous lung metastasis of an
osteosarcoma cell line KRIB. The metastasis can be blocked
by a humanized antibody against METCAM, suggesting
METCAM plays a positive role in the progression of osteo-
sarcomas [39].
3.4. METCAM and Ovarian Cancer Metastasis. Recently we
found that overexpression of METCAM/MUC18 suppressed
metastasis and ascites formation of SK-OV-3 cells in the
intraperitoneal cavity [34], as shown in Figure 15.
3.5. METCAM and Metastasis of Other Cancer Cell Lines.
Decreased expression of METCAM has been correlated with8 Journal of Oncology
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Figure 15: Enforced expression of huMETCAM in human ovarian
SK-OV-3 cells suppressed solid tumor formation and ascites forma-
tion in the intraperitoneal cavity. METCAM-clone expressed 100%
of METCAM. Vector-clone expressed 0.5% of METCAM.
the progression of haemangioma, suggesting the possible
negative eﬀectofMETCAM on progression of haemangioma
[38]. Though METCAM was downregulated in nasopha-
ryngeal carcinoma, interestingly it was upregulated again in
metastaticlesionsinnasopharyngealpatients,suggestingthat
METCAM may play a positive role in the malignant progres-
sion of nasopharyngeal carcinoma after a transient suppres-
sion of tumorigenesis [11].
Taken together, we suggest that the possible tumor and
metastasis suppressor role of METCAM may not be limited
tomelanomaandovariancancers,andthatthismaybeanew
function of METCAM yet to be explored.
Summary. Table 1 summarizes the possible role of MET-
CAM in the tumorigenesis and metastasis of various tumors/
cancers.
Taken together, huMETCAM is a tumor promoter for
prostate and breast cancers, and a metastatic gene for most
melanoma cell lines, prostate cancer, osteosarcoma, and per-
haps, breast cancer and nasopharyngeal carcinoma. It is
a tumor suppressor for a mouse melanoma subline and
ovarian cancers, and perhaps, haemangioma and nasophar-
yngeal carcinoma; it is a metastasis suppressor for a mouse
melanoma subline, ovarian cancer, and perhaps, haemangi-
oma.
4. Mechanisms of METCAM-Mediated
TumorignesisandMetastasis
How does METCAM mediate or regulate tumorigenesis and
metastasis of cancer cells? By deducing knowledge learned
from the tumorigenesis of other tumors [15–19, 42]a n d
the huMETCAM-mediated progression of melanoma [43–
45] and angiogenesis [2, 46–51], we may be able to ﬁnd some
common clues to begin understanding its mechanisms.
First, the transcriptional expression of METCAM gene
may be regulated by PKA/CREB (cAMP-responsive element
binding protein), AP-2α [44, 45], and other transcription
factors, such as SP-1, c-Myb, N-Oct2, ETs, CArG, Egr-1, and
transcription factors binding to insulin-response elements,
as shown in Figure 16 [7].
Among these potential regulators, it is well documented
that the AP-2α transcription factor plays a crucial tumor
suppressor role in the progression of melanoma, prostate,
and breast cancer [45]. It has been shown that PKA/CREB
plays a positive role in the progression of melanoma, and
perhaps also applicable to breast cancer and prostate cancer,
by inhibiting the expression of AP-2α and increasing the
expression of METCAM [45]. However, the expression level
of AP-2α in other cancers has not been explored. The roles
of other transcription regulators, tissue-speciﬁc enhancers
and repressors, epigenetic control, and control at the level
of chromatin remodeling of the gene have still yet to be
investigated [7].
Second, since the cytoplasmic tail of METCAM contains
consensus sequences potentially to be phosphorylated by
PKA, PKC,a n dCK2, it may manifest its functions by
crosstalk with various signaling pathways mediated by these
protein kinases [7]. For example, METCAM expression in
melanoma cells is reciprocally regulated by AKT,i nw h i c h
AKT up-regulates the level METCAM and overexpression of
METCAM activates endogenous AKT, which in turn inhibits
apoptosis and increases survival ability [43]. However, it
is not clear if a similar mechanism is also used in breast,
prostate, and other cancers. Also, the detailed mechanism of
how AKT up-regulates the expression of METCAM has not
been worked out. PKA, PKC,a n dCK2 may phosphorylate
the cytoplasmic tail of METCAM, which then facilitates its
interaction with FAK, thus promoting cytoskeleton remod-
eling. Alternatively, after phosphorylation of its cytoplasmic
tail by these protein kinases, METCAM may interact with
the downstream eﬀectors of Ras, activating ERK and JNK,
which in turn may transcriptionally activate the expression
of AKT or other genes that promote the proliferation and
angiogenesis of tumor cells. Though METCAM has not been
shown to be a substrate of CK2, which has been shown to
phosphorylate other CAMs,s u c ha sCD44, E-cadherin, L1-
CAM,a n dvitronectin, it is also likely that CK2 may be able
to phosphorylate METCAM [46] and link it to AKT to aﬀect
the proliferation, survival, and other tumorigenesis-related
functions of tumor cells [47].
Third, after the engagement of METCAM with the
ligand(s)orextracellularmatrix,itmaytransmittheoutside-
in signals into tumor cells by activating FAK and the
downstream-signaling components, promoting cytoskeleton
remodeling and increasing tumor cell motility and invasive-
ness [2, 7].
Fourth, from what we know about the roles of other
CAMs in the progression of other tumors [15–19, 42], it
is logical to postulate that METCAM may aﬀect cancer
cell progression by crosstalk with signaling pathways that
aﬀect apoptosis, survival and proliferation, and angiogenesis
of tumor cells [7, 18, 42]. Thus, METCAM may aﬀect
tumorigenesis and metastasis by altering the expression of
various indexes in apoptosis, survival signaling, proliferation
signaling, and angiogenesis. To support this notion, we have
found that METCAM promotes the progression of prostate
cancer cells by rendering the cells with increased proliferative
ability by elevating levels of Ki67 and PCNA, with increased
survival ability by elevating the level of phosphorylated AKT,Journal of Oncology 9
Table 1: The role of METCAM in the tumorigenesis and metastasis of various cancer cells.
Cancer cells Tumorigenesis Metastasis References
Clinical prostate cancer and human
prostate cancer cell lines Increasing Increasing (eﬀect is in the
early stage of initiation) [7, 8, 12, 13, 35, 36]
Mouse prostate carcinomas in
TRAMP mice Increasing Increasing [41]
Clinical melanoma and human
melanoma cell lines No eﬀect Increasing (eﬀect is in the
late stages) [3, 20]
Mouse melanoma cell line of K1735
subline number 3 and 10s
No eﬀect or slight
suppression
Increasing (eﬀect is in the
late stages) [9, 21]
Mouse melanoma cell line K1735
subline number 9 Suppression Suppression [22, 23] and Wu et al.
unpublished results
Angiosarcoma Increasing Not determined [7, 37] and Wu et al.
unpublished results
Human ovarian cancer cell lines
BG-1 and SK-OV-3 Suppression suppression [33, 34]
Human osteosarcoma cell lines Not determined Increasing [39]
Human breast cancer cell line MCF-7 Suppression Not determined [24]
Human breast cancer cell lines
MCF-7 and SK-BR-3 Increasing Not determined [30, 31]
Haemangiomas Suppression? Not determined [38]
Nasopharyngeal carcinoma Suppression? Not determined [7, 11]
IRE IRE IRE ETs ETs ETs ETs
CArG CArG AP2 AP2 AP2 N-Oct-3
Insulin (ETs motif) 100 bp
Cell proliferation
Cell diﬀerentiation
Lymphoid
development
Motility
invasion
Angiogenesis
Muscle cell gene
transcription
Myo-D gene
transcription
Melanoma
development
Cell proliferation
Transformation
Hematopoietic
lineage develop-
ment
Prostate cancer de-
velopment
Induced by stress
or injury, mitogens,
and 
factors
Cell proliferation
Cell death
Adhesion
Invasion
Survival
Insulin (E-box motif) Insulin (E-box motif) Hormones
cAMP
CRE
+1
Exon 1
c-Myb
CREB
SP1 Egr AP2
Cell differentiation Cell differentiation
differentiation
Figure 16: The promoter of the huMETCAM gene. The locations of various transcriptionally regulatory elements are shown in the 900bp
promoter region of the huMETCAM gene. The possible function of each element is also indicated. The promoter contains four AP-2
(activator protein-2, GCCNNNGGC), one CRE (cAMP response element, TGACGTCA), one Egr (early growth response element, CCCTG),
ﬁve SP-1 (CCGCCC), two CArG (CC(A/t)6GG), three IRE (two insulin responsive elements with E-box motif, CANNTG, and one with Ets
motif, ACGGAT), one c-Myb (coincided with one IRE with E-box motif, CACCTG), one N-Oct-3 (or brn-2, GCCTGAAT), and four Ets
elements (GGAA).
and with increased angiogenic ability by elevating levels of
VEGF, VEGFR2, and CD31 [35]; but it has no eﬀect on the
process of apoptosis. In contrast to this, METCAM promotes
the progression of melanoma cells diﬀerently by preventing
the apoptosis of melanoma cells [47]a n dr e c i p r o c a l l y
aﬀecting the expression of a survival index, phospho-AKT
[43]. Further systematic studies by using speciﬁc RNAis to
knockdown the downstream eﬀectors one-by-one in the
METCAM-expressing clones may be necessary to further
understand this aspect of mechanism.
Fifth, METCAM may mediate hematogenous spreading
of melanoma cells, which had been implicated by its expres-
sion in endothelial cells, as well as in malignant melanoma
cells [48], further shown to be present in the junctions of
endothelialcells[49,50]andessentialfortumorangiogenesis
in at least three tumor cell lines [51] and human prostate10 Journal of Oncology
cancer LNCaP cells [52]. It is highly likely that MET-
CAM expression may promote hematogenous spreading of
prostate cancer cells, similar to melanoma cells [49]. Similar
mechanisms may also be used for the METCAM-mediated
hematogenous spreading of breast cancer and osteosarcoma
cells. However, it is not known if METCAM also plays a
role in the lymphatic spread of cancer cells. Recent results
from one group showed that METCAM is one of the
lymphatic metastasis-associated genes, which is upregulated
in malignant mouse hepatocarcinoma [53]; suggesting that
METCAM may also play a role in promoting lymphatic
metastasis of cancer cells. However, the details of how
METCAM mediates hematogenous or lymphatic spreading
of cancer cells have still yet to be investigated. Labeling the
cells with viable dyes and following the process in real time
by using a newly developed nonintruding, but highly photo-
penetrating imaging method of photoacoustic tomography
(PAT) [54, 55] may be useful for monitoring each step in
the METCAM-mediated progression. For the METCAM-
mediated dynamic spreading of melanoma cells in vivo, the
PAT imaging method coupled with using hairless syngeneic
mouse animal models [56] should reveal more clearly the
process in real time.
Sixth, METCAM has been shown to express in nor-
mal mesenchymal cells (smooth muscle, endothelium, and
Schwann cells) in the tissue stroma and be a marker for
the mesenchymal stem cells [57], METCAM m a yp l a ya n
important role in regulating tumor dormancy or awakening,
driving or preventing cancer cells to premetastatic niche, and
formatting a microenvironment for favorable or unfavorable
tumor growth in secondary sites.
Seventh, METCAM may aﬀect the progression of cancer
cells by interactions with the host immune system, which,
however, has been shown to have a paradoxical role in
tumor progression [58]. Recently, one group has shown
that a subset of host B lymphocytes may control melanoma
metastasis through METCAM-dependent interaction [59].
On the other hand, it is highly likely that the tumor
suppression eﬀect of METCAM expression in melanoma
K1735-9 subline may be due to the interaction of METCAM-
expressing cells with the host immune defense system in
the immunocompetent syngeneic C3H brown mouse, since
the intrinsic motility and invasiveness of mouse melanoma
K1735-9 was increased by the METCAM expression [22, 23].
For example, the surface METCAM expressed in this partic-
ular melanoma cell line may have a homophilic interaction
withtheNK cells,whichalsoexpress METCAM andenhance
cytotoxic functions of NK cells [60]. This hypothesis should
be testable by studying the METCAM-mediated metastasis
of METCAM-expressing K1735-9 cells in various genetically
altered mice with a knockout of CD4+ T cells, CD8+ T cells,
or NK cells, or mice with a combined knockout of these
immune cells.
Eighth, malignant progression of cancer cells has been
shown to associate with an abnormal glycosylation, resulting
in expression of altered carbohydrate determinants [61].
Thus, the glycosylated status of METCAM in diﬀerent cancer
types may be diﬀerent from normal cells, thus manifesting
positive or negative eﬀect on the progression of diﬀerent
cancer types. This aspect of the METCAM-mediated cancer
progression has not been well studied, but is especially
intriguing since METCAM possesses six conserved N-gly-
cosylation sites in the extracellular domain [7, 8].
We should always keep in mind that mechanisms of
METCAM-mediated cancer progression may be slightly dif-
ferent in diﬀerent cancer cells due to their diﬀerent intrinsic
properties, which provides diﬀerent cofactors and/or dif-
ferent ligand(s) that either positively or negatively regulate
the METCAM-mediated tumorigenesis and metastasis. To
further understand the role of METCAM in these processes,
it is essential to diligently identify the cofactors and the
METCAM-cognate heterophilic ligand(s), which modulate
the biological functions of METCAM. The endeavor in this
direction appears to be promising from our preliminary
attempts that we may have successfully found a possible
candidate of METCAM’s heterophilic ligand in METCAM-
expressing human prostate cancer cells [7].
Mechanisms of METCAM-mediated negative role in the
progression of some cancer cells have not been studied at
all. Does METCAM in some cancers behave like E-cadherin,
which always plays a negative role in the tumorigenesis and
metastasis of most epithelial cancer cells [18]? But even E-
cadherin may function diﬀerently in diﬀerent cancer cells.
For example, its expression is temporally diﬀerent and corre-
l a t e sw i t hd i ﬀerent stages during the progression of ovarian
cancer [62]: E-cadherin is not expressed in the ovarian sur-
face epithelial cells, expressed in premalignant lesions and in
well-diﬀerentiated tumors, and ﬁnally not expressed in late-
stage invasive tumors [62]. Likewise, METCAM may express
andfunctionnormallyinthenormalnasopharyngealepithe-
lium, transiently reduce its expression and lose its func-
tion during the development of nasopharyngeal carcinoma,
resume its expression, and function in the invasion stage of
the cancer. Alternatively, METCAM may behave diﬀerently
fromE-cadherinbybeingmodulatedbydiﬀerentcofactorsor
ligands, which are expressed at diﬀerent stages of the cancer.
T h et u m o rs u p p r e s s o rr o l eo fMETCAM in ovarian cancer
cells may not be due to the altered intrinsic properties of
the cancer cells, since the intrinsic motility and invasiveness
of human ovarian cancer BG-1 and SK-OV-3 cells was not
aﬀected by the METCAM expression [34, 35]. Our prelim-
inary results appear to suggest a special mechanism that a
soluble form of METCAM,w h i c hi sp r o d u c e db yMMPsi n
the METCAM-expressing cells, may mediate the suppressive
eﬀect in ovarian cancer cells, similar to the production of a
soluble form of P-cadherin by the induced MMPs in breast
cancer cells, which then dictates, instead of suppresses, the
aggressive behavior of the breast cancer cells [63].
5. Conclusions andClinicalApplications
METCAM may have a key positive function in the progres-
sion of angiosarcoma, breast cancer, osteosarcoma, prostate
cancer, and most melanoma cell lines. On the other hand, it
may also have a key function in suppressing the progression
of a few melanoma cell lines, ovarian cancer, haemangioma,
and other cancers. To further understand its mechanisms inJournal of Oncology 11
these processes, it is crucial to deﬁne its functional domains,
identify its cognate ligand(s) and cofactor regulators, and
study its crosstalk with members of various signaling path-
ways [7]. These model systems may be useful for real-
time observation of the dynamic process of cancer progres-
sion by using a nonintrusive and high photo-penetrating
imaging system, such as the newly developed photoacoustic
tomography (PAT), to further understanding the process in
mouse models [54, 55]. The knowledge gained would also be
useful for designing eﬀective means to decrease, or even to
block the metastatic potential of these cancers. Along these
lines, a preclinical trial of using doxazosin,a nα1-adrenergic
antagonist that has been used to treat the BPH patients,
has been shown to be able to suppress prostate cancer
metastasis in the TRAMP mouse model [64]. Furthermore,
preclinical trials using a fully humanized anti-METCAM
antibody against melanoma growth and metastasis [65, 66]
and using a mouse anti-METCAM monoclonal antibody
against angiogenesis and tumor growth of hepatocarcinoma,
leiomyosarcoma, and pancreatic cancer [51]h a v eb e e ns u c -
cessfully demonstrated. Alternatively, small soluble peptides
derived from METCAM may also be useful for blocking the
tumor formation and tumor angiogenesis [52, 67, 68]. The
attachmentofthesereagentstonanoparticlesmaybeanother
alternative for therapeutic use [69].
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